CT Perfusion Scans in Detecting Changes in Blood Flow to the Liver After Portal Vein Embolization

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

22 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-07-21

Study Completion Date

2024-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This trial studies the use of computed tomography (CT) perfusion scans in detecting changes in blood flow to the liver after portal vein embolization in patients with liver cancer. CT perfusion scans use a standard contrast drug given by vein to measure blood flow to the liver. CT perfusion scans may predict the rate and amount of growth of new, healthy tissue on one side of the liver after a portal vein embolization and detect change to the size of the liver tumor as result of the procedure.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Pilot 3D Contrast-Enhanced Ultrasound Imaging to Predict Treatment Response in Liver Metastases

NCT01631318

Liver Metastases Colon Cancer

COMPLETED NA

Perfusion CT as a Predictor of Treatment Response in Patients With Hepatic Malignancies

NCT01163526

Neuroendocrine Tumors Brain (Nervous System) Cancers Colon/Rectal Cancer +4 more

TERMINATED

CT Volume Measurement of Hepatocellular Carcinoma

NCT07183566

Hepatocellular Carcinoma (HCC) CT

NOT_YET_RECRUITING

Prediction of Incidence of Liver Cancer by Use of Real-time Tissue Elastography

NCT01360892

Chronic Hepatitis B Chronic Hepatitis C

UNKNOWN

Can Quantitative MRI After cTACE Help Predict Survival ?

NCT02173119

Hepatocellular Carcinoma (HCC)

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

PRIMARY OBJECTIVES:

I. To assess whether perfusion changes to the liver following portal vein embolization (PVE) correlate with hypertrophy of the future liver remnant (FLR).

SECONDARY OBJECTIVES:

I. To assess perfusion changes to liver tumors following PVE. II. To assess whether PVE may affect tumor growth.

OUTLINE:

Prior to PVE, patients undergo CT perfusion scan of the liver and liver biopsy over 15 minutes. Patients undergo a second CT perfusion scan immediately after PVE and a third CT perfusion scan 3-6 weeks post PVE.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Liver and Intrahepatic Bile Duct Carcinoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Diagnostic (CT perfusion scans, liver biopsy)

Prior to PVE, patients undergo CT perfusion scan of the liver and liver biopsy over 15 minutes. Patients undergo a second CT perfusion scan immediately after PVE and a third CT perfusion scan 3-6 weeks post PVE.

Group Type EXPERIMENTAL

Computed Tomography Perfusion Imaging

Intervention Type RADIATION

Undergo perfusion CT

Liver Biopsy

Intervention Type PROCEDURE

Undergo liver biopsy

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Computed Tomography Perfusion Imaging

Undergo perfusion CT

Intervention Type RADIATION

Liver Biopsy

Undergo liver biopsy

Intervention Type PROCEDURE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Biopsy of Liver

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients planned to undergo major liver resection for cancer who need PVE to increase the size of the FLR prior to surgery.
* Patients who are able to understand and give consent to participate in the study.

Exclusion Criteria

* Pregnant or nursing.
* Allergy to iodinated contrast which cannot be safely pre-medicated.
* History of severe renal dysfunction (glomerular filtration rate \[GFR\] \< 30 mL/min/1.73 square meters). Patients with a GFR between 30-50 mL/min/1.73 square meters will receive the standard contrast-induced nephropathy prophylaxis at our institution (i.e. N-acetylcysteine and sodium bicarbonate \[150 mEq/L\] in D5W intravenous).

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No